Trimetazidine Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 20 mg
Reference Brands: Vazocardin(EU)
Category:
Heart Disorder
Trimetazidine improves cardiac metabolism by shifting energy production from fatty acids to glucose, increasing efficiency during ischemic stress. It reduces angina symptoms, enhances exercise tolerance, and protects heart tissue. Benefits include decreased angina frequency, better blood flow, reduced myocardial injury, and improved quality of life in ischemic heart disease patients.
Trimetazidine tablet is available in Tablet
and strengths such as 20 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Trimetazidine tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Trimetazidine tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Trimetazidine tablets, marketed as Vazocardin, are approved in the EU for angina and ischemic heart disease but are not approved in the US. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the EU, the EMA reviews detailed clinical trial data and ensures compliance with regional safety standards. In the US, the FDA has not authorized trimetazidine for sale, citing safety concerns. For guidance on dossier preparation, regulatory pathways, and market entry strategies, visit PharmaTradz. Proper adherence to regional regulations supports timely approval, safe use, and worldwide availability, helping to optimize treatment for ischemic heart conditions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing